7 Feb 2017 07:02
Motif Bio plc
("Motif Bio" or the "Company")
Notification and public disclosure of transactions by PDMR and persons closely associated with them
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that on 6 February 2017 it was notified that Amphion Innovations plc ("Amphion") had pledged an additional 14,500,000 ordinary shares of 1 penny each in the capital of Motif Bio as security to a draw-down of an additional tranche of Amphion's loan facility (the "Share Pledge"). In total, Amphion has pledged 42,461,625 ordinary shares in the Company in relation to the Share Pledge. As a result of the Share Pledge, Amphion will transfer legal title to but will retain the beneficial interest in these pledged ordinary shares. Richard Morgan and Robert Bertoldi, non-executive Chairman and executive director of the Company respectively, are also directors of Amphion (the "Amphion Directors"). Amphion is therefore a "Person Closely Associated" with the Amphion Directors under the Market Abuse Regulation. The Share Pledge does not change the number of ordinary shares of the Company in issue.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
|
| ||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a) | Name
| Amphion Innovations Plc | |||||
2 | Reason for the notification | ||||||
a) | Position/status
| Person Closely Associated with PDMRs of Motif Bio Plc (Robert Bertoldi and Richard Morgan) | |||||
b) | Initial notification/Amendment
| Initial Notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a) | Name | Motif Bio Plc | |||||
b) | LEI | 54930080DN00QTIUUU84 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary Shares
ISIN GB00BVVT4H71 | |||||
b) | Nature of the transaction
| Transfer of the legal but not beneficial interest in 14,500,000 Ordinary Shares by way of a pledge for a loan
| |||||
c) | Price(s) and volume(s)
|
| |||||
d) | Aggregated information
|
| |||||
e) | Date of the transaction
| 6 February 2017
| |||||
f) | Place of the transaction
| N/A | |||||
For further information please contact:
Motif Bio plc | info@motifbio.com | |
Graham Lumsden (Chief Executive Officer) |
| |
|
| |
Zeus Capital Limited (NOMAD & BROKER) | +44 (0)20 3829 5000 | |
Phil Walker/Giles Balleny |
| |
Dominic Wilson |
| |
|
| |
Northland Capital Partners Limited (BROKER) | +44 (0)203 861 6600 | |
Patrick Claridge/ David Hignell |
| |
John Howes/ Rob Rees (Broking) |
| |
|
| |
Walbrook PR Ltd. (FINANCIAL PR & IR) | +44 (0) 20 7933 8780 or motifbio@walbrookpr.com | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
Mike Wort | Mob: +44 (0)7900 608 002 | |
|
| |
MC Services AG (EUROPEAN IR) | +49 (0)89 210 2280 | |
Raimund Gabriel |
| |